Of note, remarkable studies in 2005 demonstrated that PARP inhibition selectively kills the BRCA1/2 mutant tumor cells [16, 17], leading to the rapid clinical development of PARP inhibitors (PARPi) for patients with homologous recombination (HR)-deficient cancer. The gene discussed is PARP1; the disease is neoplasm.